While the rising popularity of GLP-1s helps people to lose weight, the trend also puts Planet Fitness in a position to make gains, according to Stifel. The investment firm reiterated its buy rating on the gym chain, citing its ability to court customers amid a boom in GLP-1 usage. It also maintained a $130 price target on shares, implying 31% upside from Thursday’s close. “We believe GLP-1 users could materially boost industry membership over the next few years,” analyst Chris O’Cull said in a note. A recent franchisee-funded study found around 50% of new GLP-1 users consider joining a gym, suggesting gym membership sign-ups could rise as more patients turn to the newer class of weight-loss drugs, according to Stifel. “Planet’s approachable brand positioning and dominant share of voice should position the company well to get at least its fair share of a growing pool of GLP-1 users who want a gym membership,” O’Cull said. A newer pill version of the weight-loss drug could also make the treatment less expensive and more accessible to potential patients, contributing to an even greater rise in the drug’s usage in 2026, the analyst noted. “We would not be surprised if usage doubled again in 2026, amplifying the tailwind.” PLNT 1Y mountain Planet Fitness shares have fallen over the last 12 months. Planet Fitness stock is down 9% over the past 12 months. Most analysts who cover Planet Fitness are bullish on the stock. Of the 18 who cover it, 16 rate it a buy or strong buy, LSEG data ahows.
